Sign In
Buy ATHE
$4.42
-0.0800 (-1.78%)
At Close: Jul 31, 2026
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
07:35am, Wednesday, 04'th Dec 2024
– ATH434 is a Disease Modifying Drug Candidate Targeting Alpha-Synuclein and Iron in Parkinsonian Disorders – – Topline Data Expected in Early 2025 – MELBOURNE, Australia and SAN FRANCISCO, D
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
07:25am, Tuesday, 19'th Nov 2024
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), has announced the appointment of Abby Ma
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
07:35am, Tuesday, 12'th Nov 2024
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
07:35am, Wednesday, 06'th Nov 2024
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – – Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
07:35am, Thursday, 31'st Oct 2024
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025 Positive interim data reported from ATH434-202 Phase 2 clinical trial showin
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
07:35am, Monday, 14'th Oct 2024
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
07:35am, Friday, 11'th Oct 2024
MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
- ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Aust
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
07:35am, Monday, 30'th Sep 2024
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
- Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 2
Alterity Therapeutics to Present at MST Financial Webinar
07:35am, Wednesday, 24'th Jul 2024
MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
Alterity (ATHE) Up on Interim Data From Advance MSA Study
12:06pm, Thursday, 18'th Jul 2024
Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
07:35am, Wednesday, 17'th Jul 2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstr
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
07:25am, Wednesday, 17'th Jul 2024
– 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstr
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences' Webinar
07:22pm, Wednesday, 12'th Jun 2024
MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to dev
